.png "Janet Woodcock"){kind=small}
Robert Califf
Search results
Janet Woodcock. Janet Woodcock (born August 29, 1948) is an American physician serving as Principal Deputy Commissioner of Food and Drugs, having previously served as Acting Commissioner of the U.S. Food and Drug Administration (FDA). [2] She joined the FDA in 1986, and has held a number of senior leadership positions there, including terms as ...
- Roger Miller
- Robert Califf
Feb 17, 2022 · Learn about Dr. Janet Woodcock, the FDA’s Principal Deputy Commissioner who works with the Commissioner of Food and Drugs to develop and implement key public health initiatives and oversee the agency’s day-to-day functions. She is a leading expert in drug development, safety, and innovation, and has been honored with many awards for her achievements.
- Principal Deputy Commissioner
- Office of The Commissioner
Nov 16, 2023 · U.S. Food and Drug Administration (FDA) Principal Deputy Commissioner Dr. Janet Woodcock, who led the regulator during the height of the COVID-19 pandemic as acting chief, plans to retire early ...
Nov 17, 2023 · WOODCOCK SET TO RETIRE — Longtime FDA regulator Janet Woodcock, who has worked at the agency since 1986, plans to retire in early 2024, FDA Commissioner Robert Califf told agency staff Thursday ...
This Wednesday will be Dr. Janet Woodcock’s last day at the US Food and Drug Administration (FDA), capping a remarkable 38-year career at the agency. She’s been called one of the most powerful and influential drug regulators worldwide. Last Thursday, Focus sat down with Woodcock in her office at FDA’s White Oak campus, where she reflected ...
Nov 17, 2023 · Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday. Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at ...
Jan 30, 2024 · Janet Woodcock, the FDA's principal deputy commissioner, reflects on her more than 30 years at the agency and hints at what's next. She oversaw hundreds of drug reviews, faced Covid-19 challenges and a reorganization plan.
